Statins after 70: fewer heart attacks, no gain in independent life

Design

Randomised, double-blind, placebo-controlled trial (STAREE)

Population

9,971 adults aged 70 or more without cardiovascular disease, diabetes or dementia

Primary outcome

Major cardiovascular events; and death, dementia or persistent disability

Effect

MACE HR 0.70 (95% CI 0.61–0.82); disability-free survival HR 0.94 (0.84–1.05)

STAREE was a double-blind, placebo-controlled trial run in Australian general practices. It enrolled 9,971 community-dwelling adults aged 70 or more, mean age about 75, with no cardiovascular disease, diabetes or dementia, and randomised them to atorvastatin 40 mg or placebo.

Over a median of 5.9 years, the cardiovascular composite occurred at 10.9 versus 15.5 events per 1,000 person-years (HR 0.70, 95% CI 0.61–0.82). The second primary endpoint, a composite of death, dementia or persistent disability, did not differ (HR 0.94, 95% CI 0.84–1.05). Serious adverse events were 2.7% in both groups, though muscle, liver and diabetes-related events were more frequent on atorvastatin.

This is the first large randomised answer for primary prevention in older people. It supports offering a statin to prevent cardiovascular events, while being honest that it is not a longevity or anti-dementia drug. The conversation should centre on what the patient values.

• Offer a statin for primary prevention to fit adults over 70 when avoiding heart attack and stroke is their goal.
• Explain that the trial showed no extension of life free of dementia or disability.
• Ask about muscle symptoms and check glucose at follow-up; both were more frequent on atorvastatin.
• Discuss stopping where frailty or limited life expectancy makes event prevention less relevant.

Why it matters

This settles whether statins prevent events after 70, and reframes what they can promise.

Don't overread it

People with diabetes or established cardiovascular disease were excluded, so this does not apply to them.

The statistics, in plain English

A hazard ratio of 0.70 means about 30% fewer cardiovascular events; the interval (0.61 to 0.82) stays well below 1. For disability-free survival the interval runs from 0.84 to 1.05 and crosses 1, so no effect was shown either way.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.